Industrial Consultancy & Sponsored Research (IC&SR) , IIT Madras
Technology Category/Market
Categories: Biotechnology & Genetic Engineering, Drugs & Pharmaceutical Engineering
Industry: Biomaterials Technology, Antioxidant Technology, Regenerative Medicine, Pharmaceutical, Drug Delivery, Biomedical Engineering, Tissue Engineering, Biotechnology, Medical Devices.
Applications: Wound Healing, Tissue Regeneration, Dermatology, Ophthalmology, Orthopedics, Dental, Chronic Wounds, Cosmetic Medicine, Decellularization, Transplantation, Biocompatibility, Veterinary Medicine, Antioxidant Boosting Properties, Surface Modification, Versatile Concentrations.
Market: The global amniotic membrane (AM) market size was valued at $1,102.45M in 2020, its projected to reach $1,728.05M by 2030, registering a CAGR of 4.6% from 2021 to 2030.
Image
Problem Statement
- Wounds can lead to oxidative stress due to excessive Reactive Oxygen Species (ROS).
- Oxidative stress delays proper wound healing, damaging cells & inhibiting tissue regeneration.
- Existing wound healing treatments focus on anti-microbial, anti-inflammatory, and anti-oxidants but may not effectively combat ROS.
- There’s a need for a biomaterial that can address ROS accumulation & promote tissue regeneration.
- The instant patent application proposes to Develop an anti-oxidant incorporated Amniotic Membrane (AM) that aims to provide a more effective solution for wound healing & tissue regeneration.
Technology
The present patent discloses a method for creating an Amniotic Membrane (AM) enhanced with the antioxidant Embelin for wound healing. The resulting AM- Embelin product offers enhanced wound healing properties, making it applicable in medicals. Refer FIG 1, 2 and 3.
The method involves processing dehydrated AM from human placenta, treating it with EDTA for decellularization, preparing an Embelin solution, and coating the AM with this solution.
Here is the description of the method in points:
- Preparation: Obtain dehydrated Amniotic Membrane (AM) from a human placenta, ensuring it’s clean and sterile.
- Decellularization: Treat the dehydrated AM with a 0.02% Ethylene Diamine Tetra Acetic Acid (EDTA) solution for 2 hours at 37°C to remove cellular components.
- Embelin Solution: Prepare a solution of Embelin by dispersing it in Milli Q water at concentrations of 0.05% and 0.1%. This solution is obtained after sonication and filtration.
- Coating: Apply the Embelin solution evenly on the surface of the dehydrated AM.
- Adsorption: Allow the Embelin solution to adsorb onto the AM surface.
- Incubation: Incubate the treated AM-Embelin product horizontally at room temperature for 30 minutes and in a laminar hood for more 30 minutes.
- Result: The final product is an Amniotic Membrane incorporated with the antioxidant Embelin, ready for use in wound healing applications.
Key Features/Value Proposition
User Perspective:
- Speedy Healing: Get better faster.
- Less Scarring: Smoother healing, fewer scars.
- Help for Tough Cases.
- Less Pain: Faster healing means less discomfort.
- Many Uses: Useful in various medical areas.
Industrial Perspective:
- New Market: Explore wound care & tissue products.
- Diverse Range: Add unique wound care items.
- Competitive Edge: Has a better healing products.
- Research Support: Back research in tissue repair.
- Possible Partnerships with healthcare & research.
Technology Perspective:
- Innovative: A fresh way to heal and regenerate.
- Proven Science: Supported by research.
- Easy to Make: Can be made in bulk for patients.
- Combines biology, chemistry, & medical material growth.
- Links Lab Work to Real Life: Helps lab discoveries become real-world treatments.
Questions about this Technology?
Contact for Licensing
Research Lab
Prof. Rama S Verma
Department of Biotechnology
Intellectual Property
- IITM IDF No: 2290
- Patent Grant Number: 452649
Technology Readiness Level
TRL – 4
Experimentally validated in lab.